Can Metastatic Breast Cancer be Cured or Controlled by Chemotherapy?

Legha S.S. , Buzdar A.U. , Smith T.L. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med. 1979; 91: 847–852.

Harris J. , Morrow M. , Norton L. Malignant tumors of the breast. In: DeVita T. Jr , Hellman S. , Rosenberg S.A. , eds. Cancer: Principles & Practice of Oncology, 5th ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1997: 1557–1616.

Ross M.B. , Buzdar A.U. , Smith T.L. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. comparison of consecutive series of patients in 1950s, 1960s, and 1970s. Cancer. 1985; 55: 341–346.

Todd M. , Shoag M. , Cadman E. Survival of women with metastatic breast cancer at Yale from 1920 to 1980. J Clin Oncol. 1983; 1: 403–408.

Cold S. , Jensen N.V. , Brincker H. The influence of chemotherapy on survival after recurrence in breast cancer: a population-based study of patients treated in the 1950s, 1960s and 1970s. Eur J Cancer. 1993; 29A: 1146–1152.

Brinkley D. , Haybittle J.L. The curability of breast cancer. Lancet. 1975; 2: 95.

Brinkley D. , Haybittle J.L. Long-term survival of women with breast cancer. Lancet. 1984; 1: 1118.

Brinkley D. , Haybittle J.L. The curability of breast cancer. World J Surg. 1977; 1: 287–289.

Rutqvist L.E. , Wallgren A. Long-term survival of 458 young breast cancer patients. Cancer. 1985; 55: 658–665.

Swenerton K.D. , Legha S.S. , Smith T. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979; 29: 1552–1562.

Hortobagyi G.N. , Smith T.L. , Legha S.S. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983; 1: 776–786.

Greenberg P.A.C. , Hortobagyi G.N. , Smith T.L. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996; 14: 2197–2205.

Bonadonna G. , Valagussa P. , Moliterni A. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995; 332: 901–906.

Pedrazzini A. , Cavalli F. , Brunner K.W. Complete remission following endocrine or combined cytotoxic and hormonal treatment in advanced breast cancer. A retrospective analysis. Oncology. 1987; 44: 51–59.

Decker D.A. , Ahmann D.L. , Bisel H.F. Complete responders to chemotherapy in metastatic breast cancer: characterization and analysis. JAMA. 1979; 242: 2075–2079.

Dunphy F.R. , Spitzer G. , Fornoff J.E. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support [published erratum in Cancer. 1994; 74: 773]. Cancer. 1994; 73: 2157–2167.

Falkson G. , Holcroft C. , Gelman R.S. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1995; 13: 1453–1458.